Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14849768 | 1.00 | SLC18A3 (0.42) | SLC18A3SIGMAR1TSHRGAAMAPT | |
| SCHEMBL27967916 | 0.94 | SLC18A3 (0.42) | SLC18A3SIGMAR1TSHRGAAMAPT | |
| SCHEMBL23483033 | 0.89 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2479517 | 0.87 | SLC18A3 (0.45) | SLC18A3SIGMAR1TSHRGAAMAPT | |
| SCHEMBL23050200 | 0.87 | SLC18A3 (0.45) | SLC18A3SIGMAR1TSHRGAAMAPT | |
| SCHEMBL14849673 | 0.84 | KDM1A (0.44) | TSHRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL19094052 | 0.83 | SLC18A3 (0.47) | SLC18A3SIGMAR1TSHRGAAMAPT | |
| SCHEMBL15300702 | 0.80 | HTR3A (0.47) | SLC18A3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL25249799 | 0.80 | PRKAB2 (0.36) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL10553055 | 0.80 | SMN1; SMN2 (0.40) | SLC18A3TSHRMAPTPRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002540107-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1165540-A1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2002-01-02 | — | — | EP | claimed |
| WO-2000056727-A1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-28 | — | — | WO | claimed |
| CN-114437000-A | Method for preparing cyclic ether by dehydrating and cyclizing diol | 中国科学院化学研究所 | 2022-05-06 | — | — | CN | disclosed |
| CN-111440132-B | Novel method for preparing oxygen heterocyclic compound by ionic liquid catalysis | 中国科学院化学研究所 | 2022-02-01 | — | — | CN | disclosed |
| CN-107408734-B | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-08-18 | — | — | CN | disclosed |
| CN-111440132-A | Novel method for preparing oxygen heterocyclic compound by ionic liquid catalysis | 中国科学院化学研究所 | 2020-07-24 | — | — | CN | disclosed |
| EP-3273520-B1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS ELECTROLYTE SECONDARY CELL IN WHICH SAME IS USED | MITSUBISHI CHEM CORP (JP) | 2020-05-06 | — | — | EP | disclosed |
| CN-107078352-B | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-04-28 | — | — | CN | disclosed |
| US-10424812-B2 | Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-09-24 | — | — | US | disclosed |
| US-10424813-B2 | Non-aqueous electrolyte solution and non-aqueous electrolyte secondary battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-09-24 | — | — | US | disclosed |
| US-9593280-B2 | Liquid crystal display device | DIC CORPORATION (JP) | 2017-03-14 | — | — | US | disclosed |
| US-8765751-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| EP-1165540-A1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056728-A1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000056727-A1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| EP-0294220-B1 | Photopolymerizable composition | HITACHI CHEMICAL CO LTD (JP) | 1994-05-25 | — | — | EP | disclosed |
| US-5034429-A | An unsaturated monomer, a photoinitiator and a benzene derivative for providing a cured film | HITACHI CHEMICAL CO., LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
| EP-0294220-A2 | Photopolymerizable composition | Hitachi Chemical Co., Ltd. (JP) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | ATR, CHEK1, PLK1 | SLC18A3 1971/4885SIGMAR1 3443/4885TSHR 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.